Trophozoite elimination in a rat model of Pneumocystis carinii pneumonia by clinically achievable plasma deferoxamine concentrations

Antimicrobial Agents and Chemotherapy

Volumn 40, Issue 5, 1996, Pages 1298-1300

  Merali, Salim ^a   Chin, Kevin ^a   Grady, Robert W ^b   Clarkson Jr , Allen B ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFEROXAMINE;

AIDS RELATED COMPLEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG EFFECT; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RAT; TROPHOZOITE;

EID: 0029916993     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.40.5.1298     Document Type: Article

References (18)

1. Bartlett, M. S., and J. W. Smith, 1991. Pneumocystis carinii, an opportunist in immunocompromised patients. Clin. Microbiol Rev. 4:137-149
2. Bedrossian, C. W. M. 1989 Ultrastructure of Pneumocystis carinii: a review of internal and surface characteristics Semin. Diagn Pathol 6:212-237.
3. Boelaert, J. R., J. Van Cutsem, F. Van Gerven, and J. Fransen. 1993 Effect of desferrioxamine on experimental pneumocystosis, abstr. PO-B10-1483. In Abstracts of the IX International Conference on AIDS.
4. Chatterton, J. M. W., A. W. L. Joss, M. M. Davidson, and D. O. Ho-Yen. 1990 Why have Pneumocystis carinii trophozoites been ignored? J. Clin. Pathol. 43:265-268
5. Clarkson, A. B., M. Saric, and R. Grady. 1990. Deferuxamine and eflornithine (DL-α-difluoromethylornithine) in a rat model of Pneumocystis carinii pneumonia Antimicrob Agents Chemother. 34:1833-1835
6. Day, J. P., and P. Ackrill. 1993. The chemistry of desferrioxamine chelation for aluminum overload in renal dialysis patients. Ther. Drug Monit. 15:598-601.
7. Hallaway, P. E., and B. E. Hedlund. 1992. Therapeutic strategies to inhibit iron-catalyzed tissue damage, p. 477-458. In R. B. Lauffen (ed.), Iron and human disease. CRC Press, Inc., Boca Ratan, Fla.
8. Herbert, V., S. Shaw, E. Jayatilleke, and T. Stopler-Kasdan. 1994. Most free-radical injury is iron-related: it is promoted by iron, hemin, holoferritin and vitamin C, and inhibited by desferrioxamine and apoferritin. Stem Cells 12:289-303
9. Hershko, C., A. Pinson, and G. Link. 1990. Iron chelation. Blood Rev. 4:1-8
10. Lee, P., N. Mohammed, L. Marshall, R. D. Abeysinghe, R. C. Hider, J. B. Porter, and S. Singh. 1993. Intravenous infusion pharmacokinetics of desferrioxamine in thalassaemic patients. Drug. Metab. Dispos. 21:640-644.
11. Masur, H. 1992. Prevention and treatment of Pneumocystis carinii pneumonia. N. Engl. J. Med. 327:1853-1860.
12. Merali, S., K. Chin, R. W. Grady, M. Armstrong, and A. B. Clarkson. 1995. Clinically achievable plasma deferoxamine concentrations are therapeutic in a rat model of Pneumocystis carinii pneumonia. Antimicrob. Agents Chemother. 39:2023-2026
13. Merali, S., K. Chin, R. W. Grady, L. Weissberger, and A. B. Clarkson. 1995. Response of a rat model of PCP to continuous infusion of deferoxamine. Antimicrob Agents Chemother. 39:1442-1444.
14. Summers, M. R., A. Jacobs, D. Tudway, P. Perera, and C. Ricketts. 1979 Studies in desferrioxamine and ferrioxamine metabolism in normal and iron-loaded subjects. Br. J. Heamatol. 42:547-555.
15. Walzer, P. D. 1991. Immunopathogenesis of Pneumocystis, carinii infection. J. Lab. Clin. Med. 118:206-216.
16. Weinberg, G. A. 1994. Iron chelators as therapeutic agent against Pneumocystis carinii. Antimicrob. Agents Chemother. 38:997-1003
17. Weinberg, G. A., and M. M. Shaw. 1991. Suppressive effect of deferoxamine on the growth of Pneumocystis carinii in vitro. J. Protozool. 38:223S-224S.
18. Yoneda, K., and P. D. Walzer. 1983. Attachment of Pneumocystis carinii to type I alveolar cells studies by freeze-fracture electron microscopy. Infect. Immun. 40:812-815.